What development phase is Emetin in?

Emetin is FDA-approved (marketed).

What is the generic name of Emetin?

EMETINE is the generic (nonproprietary) name of Emetin.

Last reviewed 2026-04-20 · How we verify

Emetin (EMETINE)

FDA-approved withdrawn Small molecule Quality 15/100

At a glance

Generic name	EMETINE
Drug class	emetine
Target	Putative hydrolase RBBP9, Alpha-1D adrenergic receptor, Alpha-2A adrenergic receptor
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluating Emetine for Viral Outbreaks (EVOLVE) (PHASE2,PHASE3)
Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) (PHASE2,PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Emetin CI brief — competitive landscape report
Emetin updates RSS · CI watch RSS